News | December 13, 2011

Bracco Updates Status of CardioGen-82 Recall, Third Patient Being Tested

December 13, 2011 – During RSNA 2011, Bracco explained it is working with the U.S. Food and Drug Administration (FDA) to re-introduce CardioGen-82 (Rubidium Rb 82 Generator) since its recall this past summer.

In July 2011, the U.S. Department of Homeland Security (DHS) notified the FDA about two individuals, who had previously undergone positron emissions tomography (PET) myocardial perfusion imaging (MPI) scans with CardioGen-82, crossing U.S. borders who triggered very sensitive gamma ray emission sensors. Full body scans of those two patients at Oak Ridge National Laboratory determined the estimated amount of unexpected radiation to be minimal and similar to what other patients may receive with cumulative exposure to certain other types of cardiac imaging procedures. Bracco’s investigation regarding a third patient detected at the border remains underway.

Maintaining its commitment to patient safety, Bracco has implemented several initiatives to ensure that its products meet the highest standards, including a voluntary recall of Rubidium (Rb) 82 Generators, a clinical assessment program and an Rb-82 Generator quality review program.

In support of a market return, Bracco is in the process of revalidating its manufacturing process and reviewing labeling and user training to ensure proper generator use. Bracco has been in constant communication with the FDA to investigate the root cause of the unexpected radiation detected in the border individuals and to address the FDA’s concerns.

Bracco has proposed an orderly, phased reintroduction of CardioGen-82 generators to user facilities, with data collection and evaluation of the actual field use of each generator. Based on the outcome of its reintroduction discussions with the FDA, Bracco anticipates a limited and progressive reintroduction of the product to commence in the first or second quarter of 2012.

For more information: www.cardiogen.com

Related Content

Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...